Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -169.34%-11.16M | ---- | 132.88%16.09M | ---- | 39.96%-48.94M | ---- | -111.00%-81.51M | ---- | 8.34%-38.63M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | -8,700.00%-88K | ---- | 83.33%-1K | ---- | 14.29%-6K | ---- | -40.00%-7K | ---- | 89.13%-5K |
| Interest expense - adjustment | ---- | ---- | ---- | --4.75M | ---- | ---- | ---- | ---- | ---- | ---- |
| Attributable subsidiary (profit) loss | ---- | ---- | ---- | -99.61%3K | ---- | 17.90%764K | ---- | -67.42%648K | ---- | --1.99M |
| Impairment and provisions: | ---- | -32.29%3.54M | ---- | -55.09%5.23M | ---- | -46.51%11.65M | ---- | 28,393.51%21.79M | ---- | -119.44%-77K |
| -Impairment of property, plant and equipment (reversal) | ---- | --215K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | -36.40%3.33M | ---- | -55.09%5.23M | ---- | -46.51%11.65M | ---- | 28,393.51%21.79M | ---- | -119.44%-77K |
| Revaluation surplus: | ---- | -340.00%-638K | ---- | 53.97%-145K | ---- | 44.15%-315K | ---- | -184.81%-564K | ---- | 156.50%665K |
| -Derivative financial instruments fair value (increase) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -215.71%-486K | ---- | 137.63%420K |
| -Other fair value changes | ---- | -340.00%-638K | ---- | 53.97%-145K | ---- | -303.85%-315K | ---- | -131.84%-78K | ---- | 501.64%245K |
| Asset sale loss (gain): | ---- | 101.28%322K | ---- | -52.57%-25.15M | ---- | ---16.49M | ---- | ---- | ---- | ---9.71M |
| -Loss (gain) from sale of subsidiary company | ---- | 101.28%322K | ---- | -53.15%-25.15M | ---- | ---16.42M | ---- | ---- | ---- | ---9.71M |
| -Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | ---62K | ---- | ---- | ---- | ---- |
| Depreciation and amortization: | ---- | -1.93%13.02M | ---- | -42.22%13.27M | ---- | -29.70%22.97M | ---- | -14.87%32.68M | ---- | 49.06%38.38M |
| -Amortization of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -24.56%86K | ---- | 0.00%114K |
| Financial expense | ---- | -63.77%1.35M | ---- | -42.76%3.73M | ---- | -19.20%6.52M | ---- | -13.84%8.07M | ---- | 74.33%9.37M |
| Special items | ---- | ---- | ---- | -92.15%821K | ---- | -39.23%10.46M | ---- | 464.20%17.21M | ---- | -1,350.26%-4.73M |
| Operating profit before the change of operating capital | ---- | -65.86%6.35M | ---- | 239.14%18.61M | ---- | -694.53%-13.37M | ---- | 38.69%-1.68M | ---- | 76.07%-2.75M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | 127.40%166K | ---- | -93.70%73K | ---- | -77.69%1.16M | ---- | 103,980.00%5.19M | ---- | 99.84%-5K |
| Accounts receivable (increase)decrease | ---- | -202.44%-4.34M | ---- | -125.89%-1.44M | ---- | 12.49%5.55M | ---- | -75.69%4.93M | ---- | 191.90%20.28M |
| Accounts payable increase (decrease) | ---- | 165.71%14.59M | ---- | -435.08%-22.2M | ---- | 1,480.21%6.63M | ---- | -116.97%-480K | ---- | -94.43%2.83M |
| Special items for working capital changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%1M | ---- | -70.81%1M |
| Cash from business operations | ---- | 438.20%16.76M | ---- | -11,700.00%-4.96M | ---- | -100.47%-42K | ---- | -58.04%8.96M | ---- | 21.89%21.36M |
| Other taxs | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---23K | ---- | ---- |
| Special items of business | -44.14%3.3M | ---- | 33.63%5.91M | ---- | 310.57%4.42M | ---- | 71.40%-2.1M | ---- | 55.75%-7.34M | ---- |
| Net cash from operations | -44.14%3.3M | 438.20%16.76M | 33.63%5.91M | -11,700.00%-4.96M | 310.57%4.42M | -100.47%-42K | 71.40%-2.1M | -58.15%8.94M | 55.75%-7.34M | 27.10%21.36M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | 1,800.00%19K | ---- | -83.33%1K | ---- | -14.29%6K | ---- | 40.00%7K | ---- | -89.13%5K |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---3.57M |
| Sale of fixed assets | ---- | ---- | ---- | ---- | ---- | --220K | ---- | ---- | ---- | ---- |
| Purchase of fixed assets | ---- | 73.29%-300K | ---- | 1.40%-1.12M | ---- | 70.85%-1.14M | ---- | 73.93%-3.91M | ---- | 76.54%-14.99M |
| Sale of subsidiaries | ---- | ---- | ---- | 26.77%-93K | ---- | ---127K | ---- | ---- | ---- | ---928K |
| Recovery of cash from investments | ---- | --6.99M | ---- | ---- | ---- | ---- | ---- | --2M | ---- | ---- |
| Cash on investment | ---- | ---- | ---- | ---- | ---- | 80.99%-230K | ---- | 39.17%-1.21M | ---- | 75.20%-1.99M |
| Other items in the investment business | 70.89%-69K | ---- | 18.56%-237K | 99.76%-3K | 63.85%-291K | 56.94%-1.23M | -110.13%-805K | -102.48%-2.86M | 5,467.57%7.94M | -215.16%-1.41M |
| Net cash from investment operations | 70.89%-69K | 650.99%6.71M | 18.56%-237K | 51.32%-1.22M | 63.85%-291K | 58.10%-2.5M | -110.13%-805K | 73.91%-5.97M | 5,467.57%7.94M | 67.58%-22.88M |
| Net cash before financing | -43.02%3.23M | 480.17%23.47M | 37.30%5.67M | -142.69%-6.17M | 242.20%4.13M | -185.74%-2.54M | -583.36%-2.91M | 294.43%2.97M | 103.59%601K | 97.16%-1.53M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | 502.41%1M | ---- | -98.89%166K | ---- | 284.02%15M | ---- | 113.79%3.91M | ---- | -91.75%1.83M |
| Refund | ---- | 70.76%-9.4M | ---- | -291.61%-32.16M | ---- | 14.49%-8.21M | ---- | -111.61%-9.61M | ---- | ---4.54M |
| Issuing shares | ---- | ---- | ---- | 4,792.24%51.08M | ---- | -92.86%1.04M | ---- | --14.62M | ---- | ---- |
| Interest paid - financing | ---- | 23.81%-1.15M | ---- | 51.21%-1.51M | ---- | 59.69%-3.09M | ---- | 14.86%-7.67M | ---- | -114.53%-9.01M |
| Absorb investment income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.21M |
| Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | -3,563.04%-3.37M | ---- | 28.68%-92K | ---- | ---129K | ---- | ---- |
| Other items of the financing business | -6.94%-6.45M | ---- | -11.53%-6.04M | 43.40%-60K | -388.13%-5.41M | ---106K | 3,582.35%1.88M | ---- | -99.51%51K | ---- |
| Adjustment item of financing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --10M |
| Net cash from financing operations | -6.94%-6.45M | -604.36%-20.35M | -11.53%-6.04M | 242.82%4.04M | -388.13%-5.41M | 111.22%1.18M | 3,582.35%1.88M | 11.94%-10.49M | -99.51%51K | -133.38%-11.91M |
| Effect of rate | ---- | -99.79%5K | -99.92%1K | 5,853.66%2.36M | 45.24%1.25M | 87.11%-41K | 690.83%862K | -10,700.00%-318K | 738.46%109K | -99.19%3K |
| Net Cash | -787.60%-3.22M | 245.91%3.12M | 71.64%-363K | -56.47%-2.14M | -24.63%-1.28M | 81.83%-1.37M | -257.52%-1.03M | 44.02%-7.52M | 110.41%652K | 25.71%-13.44M |
| Begining period cash | 369.50%3.97M | 35.14%846K | 35.14%846K | -69.22%626K | -69.22%626K | -79.40%2.03M | -79.40%2.03M | -57.64%9.88M | -57.64%9.88M | -43.19%23.31M |
| Cash at the end | 54.96%750K | 369.50%3.97M | -19.06%484K | 35.14%846K | -68.00%598K | -69.22%626K | -82.43%1.87M | -79.40%2.03M | -37.65%10.64M | -57.64%9.88M |
| Cash balance analysis | ||||||||||
| Cash and bank balance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --10.64M | ---- |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | -- | -- | -- | -- | -- | -- | -- | -- | National Health Accounting Firm Co., Ltd. |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.